1. Netherlands In Vitro Diagnostics Market Outlook to 2018 -
Clinical Chemistry Genetic Testing, Haematology, Histology
and Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Report Details:
Published:December 2012
No. of Pages: 275
Price: Single User License – US$2500
Netherlands In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing,
Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Summary
GlobalData’s new report, “Netherlands In Vitro Diagnostics Market Outlook to 2018 - Clinical
Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious
Immunology and Microbiology Culture” provides key market data on the Netherlands In Vitro
Diagnostics market. The report provides value (USD million), volume (units) and average price
(USD) data for each segment and sub-segment within market categories – Immuno Chemistry,
Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology And
Cytology and Genetic Testing. The report also provides company shares and distribution shares
data for each of the aforementioned market categories. The report is supplemented with global
corporate-level profiles of the key market participants with information on company financials and
pipeline products, wherever available.
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Market size and company share data for In Vitro Diagnostics market categories – Immuno
Chemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture,
Histology And Cytology and Genetic Testing.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for

2. each of the segments and sub-segments within market categories. Data from 2004 to 2011,
forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the market categories.
- Global corporate-level profiles of key companies operating within the Netherlands In Vitro
Diagnostics market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott
Laboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for
strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Netherlands In Vitro
Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to
register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product
distribution – Identify, understand and capitalize.
Get your copy of this report @
http://www.reportsnreports.com/reports/213271-netherlands-in-vitro-diagnostics-market-outlook-to-2018-clinical-
chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-and-
microbiology-culture.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 10
1.2 List of Figures 14
2 Introduction 17
2.1 What is This Report About? 17
3 In Vitro Diagnostics In Netherlands 18
3.1 In Vitro Diagnostics, Market Segmentation 18
3.2 In Vitro Diagnostics, Netherlands, Overall Revenue ($m), USD Constant, 2004-2018 19
3.3 In Vitro Diagnostics Market, Netherlands, Revenue Mix ($m), 2011 21
3.4 In Vitro Diagnostics Market, Netherlands, Category Contribution (%), 2011 22
3.5 In Vitro Diagnostics, Netherlands, Company Share (2010-2011) 29
4 Clinical Chemistry In Netherlands 31
4.1 Clinical Chemistry, Market Segmentation 31
4.2 Clinical Chemistry Market, Netherlands, Revenue Mix ($m), 2011 32
4.3 Clinical Chemistry Market, Netherlands, Segment Contribution (%), 2011 33
4.4 Clinical Chemistry Overall Revenue, (2004-2018) 34
4.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 38

3. 4.4.2 Urine Analysis, Revenue (2004-2018) 42
4.5 Clinical Chemistry Distribution Share (2010-2011) 46
4.6 Clinical Chemistry, Netherlands, Company Share (2010-2011) 47
5 Genetic Testing In Netherlands 49
5.1 Genetic Testing, Market Segmentation 49
5.2 Genetic Testing Market, Netherlands, Revenue Mix ($m), 2011 50
5.3 Genetic Testing Market, Netherlands, Segment Contribution (%), 2011 51
5.4 Genetic Testing Overall Revenue, (2004-2018) 52
5.5 Genetic Testing Distribution Share (2010-2011) 56
5.6 Genetic Testing, Netherlands, Company Share (2010-2011) 57
6 Haematology In Netherlands 59
6.1 Haematology Market, Market Segmentation 59
6.2 Haematology Market, Netherlands, Revenue Mix ($m), 2011 60
6.3 Haematology Market, Netherlands, Segment Contribution (%), 2011 61
6.4 Haematology Overall Revenue, (2004-2018) 62
6.4.1 Haematology Reagents, Revenue (2004-2018) 66
6.4.2 Immunohaematology, Revenue (2004-2018) 70
6.4.3 Haemostasis, Revenue (2004-2018) 74
6.4.4 Haematology Rapid Tests, Revenue (2004-2018) 78
6.4.5 Haematology Cell Counters Revenue (2004-2018) 82
6.5 Haematology Distribution Share (2010-2011) 86
6.6 Haematology, Netherlands, Company Share (2010-2011) 87
7 Histology And Cytology In Netherlands 89
7.1 Histology and Cytology Market, Market Segmentation 89
7.2 Histology And Cytology Market, Netherlands, Revenue Mix ($m), 2011 90
7.3 Histology And Cytology Market, Netherlands, Segment Contribution (%), 2011 91
7.4 Histology And Cytology Overall Revenue, (2004-2018) 92
7.5 Histology And Cytology Distribution Share (2010-2011) 96
7.6 Histology And Cytology, Netherlands, Company Share (2010-2011) 97
8 Immuno Chemistry In Netherlands 99
8.1 Immuno Chemistry Market, Netherlands, Revenue Mix ($m), 2011 99
8.2 Immuno Chemistry Market, Netherlands, Segment Contribution (%), 2011 100
8.3 Immuno Chemistry Overall Revenue, (2004-2018) 101
8.3.1 Disease Specific Immunochemistry, Revenue (2004-2011) 105
8.3.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 109
8.3.3 Endocrinology Tests, Revenue, (2004-2018) 113
8.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 117
8.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 121
8.3.6 Immunochemistry Analyzers, Revenue (2004-2018) 125
8.4 Immuno Chemistry Distribution Share (2010-2011) 129
8.5 Immuno Chemistry, Netherlands, Company Share (2010-2011) 130
9 Infectious Immunology In Netherlands 132

4. 9.1 Infectious Immunology, Market Segmentation 132
9.2 Infectious Immunology Market, Netherlands, Revenue Mix ($m), 2011 133
9.3 Infectious Immunology Market, Netherlands, Segment Contribution (%), 2011 134
9.4 Infectious Immunology Overall Revenue, (2004-2018) 135
9.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018 139
9.5 Infectious Immunology Distribution Share (2010-2011) 143
9.6 Infectious Immunology, Netherlands, Company Share (2010-2011) 144
10 Microbiology Culture In Netherlands 146
10.1 Microbiology Culture, Market Segmentation 146
10.2 Microbiology Culture Market, Netherlands, Segment Contribution (%), 2011 148
10.3 Microbiology Culture Overall Revenue, (2004-2018) 149
10.3.1 Microbiology Analyzers, Revenue (2004-2018) 153
10.4 Microbiology Culture Distribution Share (2010-2011) 157
10.5 Microbiology Culture, Netherlands, Company Share (2010-2011) 158
11 Overview of Key Companies in Netherlands In Vitro Diagnostics Market 160
11.1 F. Hoffmann-La Roche Ltd. 160
11.1.1 Company Overview 160
11.1.2 Share in the Netherlands In Vitro Diagnostics Market 160
11.2 Siemens Healthcare 161
11.2.1 Company Overview 161
11.2.2 Share in the Netherlands In Vitro Diagnostics Market 161
11.3 Abbott Laboratories 162
11.3.1 Company Overview 162
11.3.2 Share in the Netherlands In Vitro Diagnostics Market 162
11.4 Beckman Coulter, Inc. 163
11.4.1 Company Overview 163
11.4.2 Share in the Netherlands In Vitro Diagnostics Market 163
11.5 Ortho-Clinical Diagnostics Inc. 164
11.5.1 Company Overview 164
11.5.2 Share in the Netherlands In Vitro Diagnostics Market 164
11.6 bioMerieux S.A. 165
11.6.1 Company Overview 165
11.6.2 Share in the Netherlands In Vitro Diagnostics Market 165
11.7 Sysmex Corporation 166
11.7.1 Company Overview 166
11.8 Bio-Rad Laboratories, Inc. 166
11.8.1 Company Overview 166
11.9 Becton, Dickinson and Company 167
11.9.1 Company Overview 167
11.10 Qiagen N.V. 167
11.10.1 Company Overview 167
11.11 DiaSorin S.p.A 168

5. 11.11.1 Company Overview 168
11.12 Gen-Probe Incorporated 168
11.12.1 Company Overview 168
11.13 Alere Inc. 169
11.13.1 Company Overview 169
11.14 Diagnostica Stago, Inc. 169
11.14.1 Company Overview 169
11.15 Danaher Corporation 170
11.15.1 Company Overview 170
11.16 PerkinElmer, Inc. 170
11.16.1 Company Overview 170
11.17 Horiba, Ltd. 171
11.17.1 Company Overview 171
11.18 Thermo Fisher Scientific Inc. 171
11.18.1 Company Overview 171
11.19 Grifols, S.A. 172
11.19.1 Company Overview 172
11.20 Life Technologies Corporation 172
11.20.1 Company Overview 172
11.21 Immucor, Inc. 173
11.21.1 Company Overview 173
11.22 Phadia AB 173
11.22.1 Company Overview 173
11.23 Mindray Medical International Limited 174
11.23.1 Company Overview 174
12 In Vitro Diagnostics Market Pipeline Products 175
12.1 Clinical Chemisty Market Pipeline Products 175
12.2 Immuno Chemistry Market Pipeline Products 178
12.3 Haematology Market Pipeline Products 187
12.4 Infectious Immunology Market Pipeline Products 189
12.5 Microbiology Culture Market Pipeline Products 196
12.6 Histology And Cytology Market Pipeline Products 197
12.7 Genetic Testing Market Pipeline Products 198
13 Financial Deals Landscape 203
13.1 Partnerships 203
13.1.1 Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For Transcreener
Epigen Methyltransferase Assay 203
13.1.2 bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 205
13.1.3 Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 207
13.1.4 Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In
Oncology 208

6. 13.1.5 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 209
13.1.6 Phthisis Diagnostics Enters Into Distribution Agreement With Elitech Group 210
13.1.7 BioDot Enters Into Co-Marketing Agreement With JOT Automation 211
13.1.8 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
Assays 212
13.1.9 CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital
Microscopy Hematology Solutions 213
13.1.10 Med BioGene Amends Licensing Agreement With Precision Therapeutics For
LungExpress Dx Test 215
13.1.11 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology
217
13.1.12 Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 218
13.1.13 CML HealthCare Enters Into Agreement With MaRS Innovation 219
13.1.14 Akrivis Technologies Enters Into Co-Development Agreement With United States
Biological 220
13.1.15 Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s Hospital
For Mesothelioma Test 221
13.1.16 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein
Array Products 222
13.1.17 GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 223
13.1.18 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB
Test 224
13.1.19 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 225
13.1.20 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 226
13.1.21 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 227
13.1.22 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus
228
13.1.23 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 230
13.1.24 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC
Test 231
13.1.25 One Lambda Enters Into Co-Marketing Agreement With CellTrend 232
13.1.26 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For
ALK Cancer Biomarker 233
13.1.27 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 234
13.1.28 Biohit Enters Into Distribution Agreement With Euro-Diagnostica For GastroPanel 235
13.1.29 Biocartis Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute
And Philips Research Europe For Oncology Diagnostics 236
13.1.30 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker
237
13.1.31 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell

7. Technology 238
13.1.32 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 239
13.1.33 Isogen Life Science Enters Into Co-Marketing Agreement With Axela For Biomarker
Analysis Platforms 240
13.1.34 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange
PCR Kit 241
13.1.35 Denator Enters Into Co-Development Agreement With Erasmus And Amsterdam Medical
For Cancer Biomarker Platform 242
13.1.36 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 243
13.1.37 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 244
13.1.38 LipoScience Enters Into Licensing Agreement With Cleveland Clinic 245
13.1.39 GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 246
13.1.40 Rubicon Genomics Enters Into Technology Integration Agreement With Kreatech
Diagnostics 247
13.1.41 NexDx Enters Into Licensing Agreement With University of California For Epigenetic
Biomarkers 248
13.1.42 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 249
13.1.43 Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay
For Sepsis 250
13.1.44 Crossbeta Biosciences, Good Biomarker Sciences And U-Protein Express Partner To
Develop Alzheimer’s Disease Biomarker 251
13.1.45 QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 252
13.1.46 Boulder Diagnostics Enters Into Licensing Agreement With RUNMC 253
14 Recent Developments 254
14.1 Legal and Regulatory 254
14.1.1 Aug 20, 2012: Agendia Receives ISO Certification For Facilities In Amsterdam And Irvine
254
14.1.2 Mar 15, 2012: QIAGEN Welcomes US Guideline Changes To Recommend HPV Testing As
Part Of Cervical Cancer Screening 254
14.2 Product News 256
14.2.1 Aug 20, 2012: IntegenX Launches First RapidHIT Human DNA Identification System In
Europe 256
14.2.2 Jul 18, 2012: Hologic Secures NVVP Approval For Cervista HPV HR Test 256
14.2.3 Jun 01, 2012: Agendia Launches ColoPrint For Colon Cancer Prognosis And Prediction
257
14.2.4 Nov 24, 2011: ProQares And RPS Announce Partnership To Deploy ‘RPS Chemical Nerve
Agent Detector’ Internationally 257
14.2.5 Sep 19, 2011: Breast Cancer Research and Treatment Highlights Development And
Validation Of BluePrint 258
14.2.6 Aug 05, 2011: QIAGEN Completes Second US Submission For therascreen KRAS RGQ

8. PCR Kit To Guide Treatment Decisions In Colorectal Cancer 258
14.2.7 Mar 15, 2011: DiagnOptics Receives Health Canada Approval For AGE Reader 259
15 Appendix 260
15.1 Definitions of Markets Covered in the Report 261
In Vitro Diagnostics 261
15.2 Research Methodology 272
15.3 Secondary Research 272
15.4 Primary Research 273
15.5 Models 273
15.6 Forecasts 274
15.7 Expert Panels 274
15.8 GlobalData Consulting 274
15.9 Currency Conversion 275
15.10 Contact Us 275
15.11 Disclaimer 275
1.1 List of Tables
Table 1: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), USD Constant, 2004-2018 20
Table 2: In Vitro Diagnostics Market, Netherlands, Category Contribution (%), 2011 22
Table 3: In Vitro Diagnostics Market, Netherlands Cross-Category Analysis, 2004-2018 24
Table 4: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), USD Constant, Historic, 2004-
2011 26
Table 5: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), USD Constant, Forecast, 2011-
2018 28
Table 6: In Vitro Diagnostics, Netherlands, Company Share by Revenue ($m), USD Constant,
2010-2011 30
Table 7: Clinical Chemistry Market, Netherlands, Segment Contribution (%), 2011 33
Table 8: Clinical Chemistry, Netherlands, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 35
Table 9: Clinical Chemistry, Netherlands, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 37
Table 10: Clinical Chemisty Analyzers, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 39
Table 11: Clinical Chemisty Analyzers, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 41
Table 12: Urine Analysis, Netherlands, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 43
Table 13: Urine Analysis, Netherlands, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 45
Table 14: Clinical Chemistry, Netherlands, Distribution Share by Revenue ($m), USD Constant,
2010-2011 46
Table 15: Clinical Chemistry, Netherlands, Company Share by Revenue ($m), USD Constant,

9. 2010-2011 48
Table 16: Genetic Testing Market, Netherlands, Segment Contribution (%), 2011 51
Table 17: Genetic Testing, Netherlands, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 53
Table 18: Genetic Testing, Netherlands, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 55
Table 19: Genetic Testing, Netherlands, Distribution Share by Revenue ($m), USD Constant,
2010-2011 56
Table 20: Genetic Testing, Netherlands, Company Share by Revenue ($m), USD Constant, 2010-
2011 58
Table 21: Haematology Market, Netherlands, Segment Contribution (%), 2011 61
Table 22: Haematology, Netherlands, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 63
Table 23: Haematology, Netherlands, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 65
Table 24: Haematology Reagents, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 67
Table 25: Haematology Reagents, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 69
Table 26: Immunohaematology, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 71
Table 27: Immunohaematology, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 73
Table 28: Haemostasis, Netherlands, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 75
Table 29: Haemostasis, Netherlands, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 77
Table 30: Haematology Rapid Tests, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 79
Table 31: Haematology Rapid Tests, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 81
Table 32: Haematology Cell Counters, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 83
Table 33: Haematology Cell Counters, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 85
Table 34: Haematology, Netherlands, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 86
Table 35: Haematology, Netherlands, Company Share by Revenue ($m), USD Constant, 2010-
2011 88
Table 36: Histology And Cytology Market, Netherlands, Segment Contribution (%), 2011 91
Table 37: Histology And Cytology, Netherlands, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 93

10. Table 38: Histology And Cytology, Netherlands, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 95
Table 39: Histology And Cytology, Netherlands, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 96
Table 40: Histology And Cytology, Netherlands, Company Share by Revenue ($m), USD
Constant, 2010-2011 98
Table 41: Immuno Chemistry Market, Netherlands, Segment Contribution (%), 2011 100
Table 42: Immuno Chemistry, Netherlands, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 102
Table 43: Immuno Chemistry, Netherlands, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 104
Table 44: Disease Specific Immunochemistry, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 106
Table 45: Disease Specific Immunochemistry, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 108
Table 46: Drugs of Abuse / Toxicology, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 110
Table 47: Drugs of Abuse / Toxicology, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 112
Table 48: Endocrinology Tests, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 114
Table 49: Endocrinology Tests, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 116
Table 50: Immunochemistry Rapid Tests, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 118
Table 51: Immunochemistry Rapid Tests, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 120
Table 52: Therapeutic Drug Monitoring, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 122
Table 53: Therapeutic Drug Monitoring, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 124
Table 54: Immunochemistry Analyzers, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 126
Table 55: Immunochemistry Analyzers, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 128
Table 56: Immuno Chemistry, Netherlands, Distribution Share by Revenue ($m), USD Constant,
2010-2011 129
Table 57: Immuno Chemistry, Netherlands, Company Share by Revenue ($m), USD Constant,
2010-2011 131
Table 58: Infectious Immunology Market, Netherlands, Segment Contribution (%), 2011 134
Table 59: Infectious Immunology, Netherlands, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 136

11. Table 60: Infectious Immunology, Netherlands, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 138
Table 61: Infectious Immunology Rapid Tests, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 140
Table 62: Infectious Immunology Rapid Tests, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 142
Table 63: Infectious Immunology, Netherlands, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 143
Table 64: Infectious Immunology, Netherlands, Company Share by Revenue ($m), USD Constant,
2010-2011 145
Table 65: Microbiology Culture Market, Netherlands, Segment Contribution (%), 2011 148
Table 66: Microbiology Culture, Netherlands, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 150
Table 67: Microbiology Culture, Netherlands, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 152
Table 68: Microbiology Analyzers, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 154
Table 69: Microbiology Analyzers, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 156
Table 70: Microbiology Culture, Netherlands, Distribution Share by Revenue ($m), USD Constant,
2010-2011 157
Table 71: Microbiology Culture, Netherlands, Company Share by Revenue ($m), USD Constant,
2010-2011 159
Table 72: Clinical Chemisty Market Pipeline Products 175
Table 73: Immuno Chemistry Market Pipeline Products 178
Table 74: Haematology Market Pipeline Products 187
Table 75: Infectious Immunology Market Pipeline Products 189
Table 76: Microbiology Culture Market Pipeline Products 196
Table 77: Histology And Cytology Market Pipeline Products 197
Table 78: Genetic Testing Market Pipeline Products 198
Table 79: Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For
Transcreener Epigen Methyltransferase Assay 203
Table 80: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 205
Table 81: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 207
Table 82: Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In
Oncology 208
Table 83: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 209
Table 84: Phthisis Diagnostics Enters Into Distribution Agreement With Elitech Group 210
Table 85: BioDot Enters Into Co-Marketing Agreement With JOT Automation 211
Table 86: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
Assays 212

12. Table 87: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital
Microscopy Hematology Solutions 213
Table 88: Med BioGene Amends Licensing Agreement With Precision Therapeutics For
LungExpress Dx Test 215
Table 89: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon
Biotechnology 217
Table 90: Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 218
Table 91: CML HealthCare Enters Into Agreement With MaRS Innovation 219
Table 92: Akrivis Technologies Enters Into Co-Development Agreement With United States
Biological 220
Table 93: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s
Hospital For Mesothelioma Test 221
Table 94: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein
Array Products 222
Table 95: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 223
Table 96: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium
TB Test 224
Table 97: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 225
Table 98: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 226
Table 99: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
227
Table 100: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For
AdenoPlus 228
Table 101: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 230
Table 102: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4
POC Test 231
Table 103: One Lambda Enters Into Co-Marketing Agreement With CellTrend 232
Table 104: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics
For ALK Cancer Biomarker 233
Table 105: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 234
Table 106: Biohit Enters Into Distribution Agreement With Euro-Diagnostica For GastroPanel 235
Table 107: Biocartis Enters Into Co-Development Agreement With Wellcome Trust Sanger
Institute And Philips Research Europe For Oncology Diagnostics 236
Table 108: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG
Marker 237
Table 109: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor
Cell Technology 238
Table 110: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 239
Table 111: Isogen Life Science Enters Into Co-Marketing Agreement With Axela For Biomarker
Analysis Platforms 240

13. Table 112: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For
LongRange PCR Kit 241
Table 113: Denator Enters Into Co-Development Agreement With Erasmus And Amsterdam
Medical For Cancer Biomarker Platform 242
Table 114: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 243
Table 115: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 244
Table 116: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 245
Table 117: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 246
Table 118: Rubicon Genomics Enters Into Technology Integration Agreement With Kreatech
Diagnostics 247
Table 119: NexDx Enters Into Licensing Agreement With University of California For Epigenetic
Biomarkers 248
Table 120: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 249
Table 121: Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT
Assay For Sepsis 250
Table 122: Crossbeta Biosciences, Good Biomarker Sciences And U-Protein Express Partner To
Develop Alzheimer’s Disease Biomarker 251
Table 123: QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 252
Table 124: Boulder Diagnostics Enters Into Licensing Agreement With RUNMC 253
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation 18
Figure 2: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), USD Constant, 2004-2018 19
Figure 3: In Vitro Diagnostics Market, Netherlands, Revenue Mix ($m), 2011 21
Figure 4: In Vitro Diagnostics Market, Netherlands, Category Contribution (%), 2011 22
Figure 5: In Vitro Diagnostics Market, Netherlands Cross-Category Analysis, 2004-2018 23
Figure 6: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), USD Constant, Historic, 2004-
2011 25
Figure 7: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 27
Figure 8: In Vitro Diagnostics, Netherlands, Company Share (%), 2011 29
Figure 9: Clinical Chemistry, Market Segmentation 31
Figure 10: Clinical Chemistry Market, Netherlands, Revenue Mix ($m), 2011 32
Figure 11: Clinical Chemistry Market, Netherlands, Segment Contribution (%), 2011 33
Figure 12: Clinical Chemistry, Netherlands, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 34
Figure 13: Clinical Chemistry, Netherlands, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 36
Figure 14: Clinical Chemisty Analyzers, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 38

14. Figure 15: Clinical Chemisty Analyzers, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 40
Figure 16: Urine Analysis, Netherlands, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 42
Figure 17: Urine Analysis, Netherlands, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 44
Figure 18: Clinical Chemistry, Netherlands, Company Share (%), 2011 47
Figure 19: Genetic Testing, Market Segmentation 49
Figure 20: Genetic Testing Market, Netherlands, Revenue Mix ($m), 2011 50
Figure 21: Genetic Testing Market, Netherlands, Segment Contribution (%), 2011 51
Figure 22: Genetic Testing, Netherlands, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 52
Figure 23: Genetic Testing, Netherlands, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 54
Figure 24: Genetic Testing, Netherlands, Company Share (%), 2011 57
Figure 25: Haematology Market, Market Segmentation 59
Figure 26: Haematology Market, Netherlands, Revenue Mix ($m), 2011 60
Figure 27: Haematology Market, Netherlands, Segment Contribution (%), 2011 61
Figure 28: Haematology, Netherlands, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 62
Figure 29: Haematology, Netherlands, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 64
Figure 30: Haematology Reagents, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 66
Figure 31: Haematology Reagents, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 68
Figure 32: Immunohaematology, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 70
Figure 33: Immunohaematology, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 72
Figure 34: Haemostasis, Netherlands, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 74
Figure 35: Haemostasis, Netherlands, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 76
Figure 36: Haematology Rapid Tests, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 78
Figure 37: Haematology Rapid Tests, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 80
Figure 38: Haematology Cell Counters, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 82
Figure 39: Haematology Cell Counters, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 84

15. Figure 40: Haematology, Netherlands, Company Share (%), 2011 87
Figure 41: Histology and Cytology Market, Market Segmentation 89
Figure 42: Histology And Cytology Market, Netherlands, Revenue Mix ($m), 2011 90
Figure 43: Histology And Cytology Market, Netherlands, Segment Contribution (%), 2011 91
Figure 44: Histology And Cytology, Netherlands, Revenue ($m) USD Constant, by Segment,
Historic, 2004-2011 92
Figure 45: Histology And Cytology, Netherlands, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 94
Figure 46: Histology And Cytology, Netherlands, Company Share (%), 2011 97
Figure 47: Immuno Chemistry Market, Netherlands, Revenue Mix ($m), 2011 99
Figure 48: Immuno Chemistry Market, Netherlands, Segment Contribution (%), 2011 100
Figure 49: Immuno Chemistry, Netherlands, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 101
Figure 50: Immuno Chemistry, Netherlands, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 103
Figure 51: Disease Specific Immunochemistry, Netherlands, Revenue ($m) USD Constant, by
Sub-Segment, Historic, 2004-2011 105
Figure 52: Disease Specific Immunochemistry, Netherlands, Revenue ($m) USD Constant, by
Sub-Segment, Forecast, 2011-2018 107
Figure 53: Drugs of Abuse / Toxicology, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 109
Figure 54: Drugs of Abuse / Toxicology, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 111
Figure 55: Endocrinology Tests, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 113
Figure 56: Endocrinology Tests, Netherlands, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 115
Figure 57: Immunochemistry Rapid Tests, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 117
Figure 58: Immunochemistry Rapid Tests, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 119
Figure 59: Therapeutic Drug Monitoring, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 121
Figure 60: Therapeutic Drug Monitoring, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 123
Figure 61: Immunochemistry Analyzers, Netherlands, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 125
Figure 62: Immunochemistry Analyzers, Netherlands, Revenue ($m) USD Const
Contact: sales@reportsandreports.com for more information.